Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic focus on
immuno-oncology, announces the filing of key European patents for its chimeric PD-1 (chPD1) target.

Kiromic chPD1 receptor targets PD-1 ligands expressed on many different types of cancer cells, including ovarian,